| | | |  | | | | By Angus Chen Adobe Emerging research casts doubt on whether radiation therapy after surgery actually benefits patients with certain thyroid cancers. Read More | | By Adam Feuerstein Nektar The negative trial results cast significant doubt on the future of Nektar’s lead pipeline drug called bempegaldesleukin. Read More | | Sponsor content by NATERA Detecting recurrence early in high risk breast cancer with a personalized ctDNA test Personalized testing for circulating tumor DNA (ctDNA) can help catch recurrence early in post-treatment surveillance for high risk breast cancer patients, potentially improving their outcomes. Serial monitoring for presence of ctDNA after primary treatment can inform follow-up care. In a clinical study, a ctDNA assay custom built from each patient's unique tumor detected molecular residual disease (MRD) up to two years ahead of imaging and other indicators. Learn more. | | By Matthew Herper Emilie Pickering for STAT The news that Gilead dropped about its drug breast cancer drug Trodelvy was the latest in a string of disappointments. Read More | |
No comments